Skip to main content
. 2012 Jul;28(7):667–674. doi: 10.1089/aid.2010.0355

Table 1.

Demographic and Immunologic Characteristics of n=103 Antiretroviral-Naive Patients Included in This Study

Characteristic All patients n (or median) % (or min.–max.) Without TDR (WHO SDRM criteria) n (or median) % (or min.–max.) With TDR (WHO SDRM criteria) n (or median) % (or min.–max.) OR [95% CI] p-value
Total 103 100.0% 95 100.0% 8 100.0%
Men 47 46.1% 43 45.7% 4 50.0% 1.19 [0.28, 5.03] 0.82
Age at time of test (years) 38.6 17.8–62.5 38.9 17.8–62.5 35.4 24.0–55.7 0.25
Time since diagnosis (years) 3.0 0–19.0 3.5 0–19.0 1.0 0–7.0 0.08
HIV risk factor
 Heterosexual sex 82 82.8% 76 83.5% 6 75.0% 1.0
 MSM 10 10.1% 9 9.9% 1 12.5% 1.41 [0.15, 13.05] 0.76
 Other/multiple/unknown 7 7.1% 6 6.6% 1 12.5% 2.11 [0.22, 20.52] 0.52
Received sdNVP for PMTCT (females only) 7 13.7% 7 13.7% 0 0% 1.00
HIV status of past/current partners
 Negative 13 13.0% 12 13.0% 1 12.5% 1.0
 Positive 53 53.0% 48 52.2% 5 62.5% 1.25 [0.13, 11.72] 0.85
 Don't know 34 34.0% 32 34.8% 2 25.0% 0.75 [0.06, 9.05] 0.82
Prior/active commercial sex work 15 15.0% 13 14.1% 2 25.0% 2.03 [0.37, 11.14] 0.34
Number of lifetime partners 4 0–300 4 0–300 3.5 0–33 0.88
Prior travel outside the DR 10 9.9% 9 9.7% 1 12.5% 1.33 [0.15, 12.10] 0.80
Baseline1 laboratory studies
 CD4+ count (cells/μl) 216 5–724 218 5–724 185 101–236 0.28
 HIV-1 plasma RNA (copies/ml) 59,604 320–2,836,323 61,919 320–2,836,323 23,226 4,618–102,185 0.25
1

Baseline CD4 and HIV-1 plasma RNA level values were defined as those measured from 1 year prior to the genotype date and for up to 7 days afterward (provided ART had not yet been initiated).

sdNVP, single-dose nevirapine; PMTCT, prevention of mother-to-child transmission; MSM, men who have sex with men; DR, Dominican Republic.